Neurocrine Biosciences
NBIX
#1521
Rank
NZ$19.81 B
Marketcap
$198.75
Share price
-0.39%
Change (1 day)
-15.42%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.22

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.42. In 2022 the company made an earnings per share (EPS) of $2.81 an increase over its 2021 EPS that were of $1.66.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2214.8%
2022$2.8169.47%
2021$1.66-78.21%
2020$7.60990%
2019$0.7081.82%
2018$0.38-113.5%
2017-$2.840.62%
2016-$2.8257.28%
2015-$1.8025.61%
2014-$1.4318.84%
2013-$1.20-1085.71%
2012$0.12-89.71%
2011$1.19-500%
2010-$0.30-86.92%
2009-$2.27-43.48%
2008-$4.01-57.8%
2007-$9.5092.58%
2006-$4.93371.67%
2005-$1.05-52.76%
2004-$2.2136.56%
2003-$1.62-70%
2002-$5.40118.31%
2001-$2.488.4%
2000-$2.2848.86%
1999-$1.53-20%
1998-$1.92-479.31%
1997$0.51

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.64 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.96-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$5.16-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.47 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.42 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.24-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.82-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$5.28-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA